Development of a Fit-For-Purpose Multi-Marker Panel for Early Diagnosis of Pancreatic Ductal Adenocarcinoma
Molecular & Cellular Proteomics · 2024
DOI: 10.1016/j.mcpro.2024.100824 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2024. Verfasst von Hyeonji Kim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Bertis R&D Division, Bertis Inc, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Biomarkers, Tumor, Pancreatic Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) suffers from a lack of an effective diagnostic method, which hampers improvement in patient survival. Carbohydrate antigen 19-9 (CA19-9) is the only FDA-approved blood biomarker for PDAC, yet its clinical utility is limited due to suboptimal performance. Liquid chromatography-mass spectrometry (LC-MS) has emerged as a burgeoning technology in clinical proteomics for the discovery, verification, and validation of novel biomarkers. A plethora of protein biomarker candidates for PDAC have been identified using LC-MS, yet few has successfully transitioned into clinical practice. This translational standstill is owed partly to insufficient considerations of practical needs and perspectives of clinical implementation during biomarker development pipelines, such as demonstrating the analytical robustness of proposed biomarkers which is critical for transitioning from research-grade to clinical-grade assays. Moreover, the throughput and cost-effectiveness of proposed assays ought to be considered concomitantly from the early phases of the biomarker pipelines for enhancing widespread adoption in clinical settings. Here, we developed a fit-for-purpose multi-marker panel for PDAC diagnosis by consolidating analytically robust biomarkers as well as employing a relatively simple LC-MS protocol. In the discovery phase, we comprehensively surveyed putative PDAC biomarkers from both in-house data and prior studies. In the verification phase, we developed a multiple-reaction monitoring (MRM)-MS-based proteomic assay using surrogate peptides that passed stringent analytical validation tests. We adopted a high-throughput protocol including a short gradient (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bertis R&D Division, Bertis Inc, Gyeonggi-do, Republic of Korea.
- Bertis Inc, Seoul, Republic of Korea.
- Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Manufacturing and Technology Division, Bertis Inc, Gyeonggi-do, Republic of Korea.
- Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: jangjy4@snu.ac.kr.
- Bertis R&D Division, Bertis Inc, Gyeonggi-do, Republic of Korea. Electronic address: unbeom.kang@bertis.com.
Zitieren
APA
Kim, H., Huh, S., Park, J., Han, Y., Ahn, K. G., Noh, Y., Lee, S. J., Chu, H., Kim, S. S., Jung, H. S., Yun, W. G., Cho, Y. J., Kwon, W., Jang, J. Y., & Kang, U. B. (2024). Development of a Fit-For-Purpose Multi-Marker Panel for Early Diagnosis of Pancreatic Ductal Adenocarcinoma. Molecular & Cellular Proteomics. https://doi.org/10.1016/j.mcpro.2024.100824
Vancouver
Kim H, Huh S, Park J, Han Y, Ahn KG, Noh Y, et al. Development of a Fit-For-Purpose Multi-Marker Panel for Early Diagnosis of Pancreatic Ductal Adenocarcinoma. Molecular & Cellular Proteomics. 2024. doi:10.1016/j.mcpro.2024.100824
BibTeX
@article{Kim2024,
author = {Kim, Hyeonji and Huh, Sunghyun and Park, Jungkap and Han, Youngmin and Ahn, Kyung-Geun and Noh, Yiyoung and Lee, Seong-Jae and Chu, Hyosub and Kim, Sung-Soo and Jung, Hye-Sol and Yun, Won-Gun and Cho, Young Jae and Kwon, Wooil and Jang, Jin-Young and Kang, Un-Beom},
title = {Development of a Fit-For-Purpose Multi-Marker Panel for Early Diagnosis of Pancreatic Ductal Adenocarcinoma},
journal = {Molecular & Cellular Proteomics},
year = {2024},
doi = {10.1016/j.mcpro.2024.100824}
}
EUVIMED